Mutual of America Capital Management 13F: Adds $5.2M to LIVN Stake

Mutual of America Capital Management added 68,084 shares of LivaNova PLC LIVN during the quarter, according to a Form 13F filing with the SEC on October 23, 2026. The purchase lifted the firm's stake by 342.9%, bringing its total holding to 87,935 shares with a reported value of $6,727,028.

LIVN LivaNova PLC

$80.90 ▲ +33.41% year to date

1M 3M YTD

Daily close · Oct 23, 2026

What Changed in Mutual of America Capital Management's LivaNova Position

Before the filing, Mutual of America Capital Management held 19,851 shares of the medical technology company. The addition of 68,084 shares marked a 342.9% expansion of the position, making it a much larger part of the firm's portfolio holdings by the end of the reported period.

Other Institutional Activity in LivaNova

Other large investors adjusted their positions in LivaNova PLC around the same time. Primecap Management Company reduced its holdings by 38,705 shares, ending with 4,168,377 shares worth about $337,221,705. Hood River Capital Management LLC grew its holdings by 1,928,930 shares, ending with 2,565,477 shares worth about $207,547,093. AQR Capital Management, LLC reduced its holdings by 138,189 shares, ending with 2,356,191 shares worth about $190,615,855. Artisan Partners Limited Partnership grew its holdings by 101,898 shares, ending with 2,224,763 shares worth about $179,983,330. American Century Companies Inc grew its holdings by 218,807 shares, ending with 2,013,774 shares worth about $162,914,319.

LivaNova PLC Stock Up 3.1%

LivaNova shares recently traded around $80.90 as of October 24, 2026, roughly matching the event close price of $80.90 on October 23, 2026. The stock sits above its 50-day moving average of $78.53 and its 200-day moving average of $72.38. The company has a market capitalization of roughly $4.46 billion, a 52-week high of $85.76, and a 52-week low of $48.82.

Recent Earnings

LivaNova reported $1.47 billion in trailing twelve-month revenue with earnings of $3.38 per share. The business reported a net profit margin of 12.8% and a return on equity of 15.4%, alongside year-over-year revenue growth of 10.8%. The company is scheduled to release its next financial results on November 4, 2026.

Insider Buying and Selling at LivaNova PLC

Company insiders completed several transactions prior to the filing. Officer Ahmet Tezel sold 2,675 shares on August 11, 2026, at an average price of $77.74 for a total value of $207,942. Director Francesco Bianchi sold 1,650 shares on August 31, 2026, at $79.72 per share for $131,538. Director Brooke Story sold 2,300 shares on September 4, 2026, at $81.42 per share for $187,270. Director Francesco Bianchi sold 3,500 shares on September 10, 2026, at $78.01 per share for $273,032.

Analysts Set New Price Targets

Freedom Capital Markets initiated coverage on July 1, 2026, with a hold rating and an $81.00 price target. Mizuho maintained an outperform rating and raised its target from $90.00 to $95.00 on July 15, 2026. Needham maintained a buy rating and raised its target from $81.00 to $93.00 on August 5, 2026. Piper Sandler reiterated an overweight rating and raised its target from $87.00 to $90.00 on September 2, 2026. Barclays initiated coverage with an overweight rating and a $105.00 price target on October 7, 2026. The stock carries a consensus buy rating and a mean price target of $90.55 across 11 analyst opinions.

About LivaNova

LivaNova PLC is a medical technology company headquartered in Gloucester, United Kingdom. It designs, manufactures, and markets medical devices and therapies across two primary segments: Cardiopulmonary and Neuromodulation. Its product lines include heart-lung machines, oxygenators, and neuromodulation systems used by healthcare providers worldwide.

Bottom Line

Investors are keeping an eye on LivaNova as the company prepares to report earnings on November 4, 2026. Institutional interest remains active, while share prices hold above key moving averages.